CRISPR Therapeutics AG
$39.10+$0.17 (+0.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $5.5B
- Revenue
- $0.00
- ROCE
- -34.6%
Price chart
Technical chartScreen technicals →-20.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -21.6%
- 3M
- -32.7%
- 6M
- -19.5%
- 1Y
- -20.7%
- 5Y
- -52.6%
52-week range
Day change +$0.17 (+0.4%) from $39 to $39 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in CRSP, bought on each weekday since 2021.
News & filings
What CRISPR Therapeutics AG filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 582 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are more than ten times current liabilities.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Read moreShow less
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Shares outstanding
- 95.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $5.5B
- P/B
- 2.9x
- 52-week high
- $61.89
- 52-week low
- $38.93
Profitability
- ROE
- -30.3%
- ROCE
- -34.6%
- ROIC
- -29.5%
- ROA
- -25.7%
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $0.00
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -100.0%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 58.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$370.9M
Solvency
- Current ratio
- 13.32
- Debt / Equity
- 0.11
- Debt / Assets
- 0.09
- CFO / Net profit
- 0.59
- Cash / Market cap
- 36.0%
Revenue and net profit
Revenue fell 100.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $436.0k | -$650.2M |
| FY2023 | $370.0M | -$153.6M |
| FY2024 | $35.0M | -$366.3M |
| FY2025 | $0.00 | -$581.6M |
Cash flows
FY2025: -$345.0M from operations, -$370.9M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$495.7M | -$532.9M |
| FY2023 | -$260.4M | -$272.3M |
| FY2024 | -$142.8M | -$144.7M |
| FY2025 | -$345.0M | -$370.9M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $0.00-100.0%1Y
- EBITDA
- -$645.1M
- Net profit
- -$581.6M
- Cash from operations
- -$345.0M
- Free cash flow
- -$370.9M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $0.00 | -$645.1M | -$581.6M | -$370.9M | -30.3% | -100.0% | +58.8% |
Monthly returns
Month-by-month returns of CRSP across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $2.3B |
| Current assets | $2.0B |
| Non-current assets | $279.6M |
| Liabilities | $343.4M |
| Current liabilities | $149.1M |
| Non-current liabilities | $194.3M |
| Equity | $1.9B |
| Paid-in capital | $3.9B |
| Retained earnings | -$1.9B |
| Treasury stock | $60.0k |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CRSP highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): CRISPR Therapeutics AG, Cogent Biosciences, Inc., Scholar Rock Holding Corporation.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| CRISPR Therapeutics AGCRSPthis company | $5.5B | — | 2.9x | -30.3% | — |
| Rhythm Pharmaceuticals, Inc.RYTM | $6.0B | — | 22.3x | -74.8% | — |
| PACS Group, Inc.PACS | $5.9B | 31.0x | 6.3x | 20.2% | 25.0x |
| Mirum Pharmaceuticals, Inc.MIRM | $5.6B | -241.4x | 17.9x | -7.4% | 329.1x |
| Cogent Biosciences, Inc.COGT | $5.6B | -17.0x | 10.2x | -60.1% | -17.2x |
| Liquidia CorporationLQDA | $5.6B | -80.7x | 124.3x | -154.0% | -128.8x |
| Scholar Rock Holding CorporationSRRK | $5.4B | — | 22.1x | -154.0% | — |
| Xenon Pharmaceuticals Inc.XENE | $5.1B | -14.8x | 8.8x | -59.5% | -13.3x |
| CG Oncology, Inc.CGON | $4.9B | -30.7x | 6.6x | -21.4% | -26.0x |
| Peer median | — | -23.9x | 14.1x | -59.8% | -15.3x |
Year-to-date ROI
CRSP since 1 January, against earlier years.
Historical volatility
CRSP's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -152990.9% |
| FY2023 | -60.1% |
| FY2024 | -1333.1% |
| FY2025 | — |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Cost of revenueCost Of Revenue | $213.5M |
| Gross profitGross Profit | -$213.5M |
| Operating expensesOperating Expense | $451.1M |
| Research and developmentResearch And Development | $381.1M |
| Selling, general and administrativeSelling General And Administration | $73.5M |
| Other operating expensesOther Operating Expenses | -$3.5M |
| Total expensesTotal Expenses | $664.6M |
| Operating incomeOperating Income | -$664.6M |
| Interest and other | |
| Pretax incomePretax Income | -$578.0M |
| TaxTax Provision | $3.6M |
| Net incomeNet Income | -$581.6M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $2.3B |
| Current assetsCurrent Assets | $2.0B |
| Non-current assetsTotal Non Current Assets | $279.6M |
| LiabilitiesTotal Liabilities Net Minority Interest | $343.4M |
| Current liabilitiesCurrent Liabilities | $149.1M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $194.3M |
| EquityTotal Equity Gross Minority Interest | $1.9B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$345.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$345.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$581.6M |
| Depreciation and amortisationDepreciation And Amortization | $19.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $19.5M |
| Depreciation | $19.4M |
| Amortization of securitiesAmortization Of Securities | — |
| Stock-based compensationStock Based Compensation | $72.5M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | — |
| Change in working capitalChange In Working Capital | $71.9M |
| Other non-cash itemsOther Non Cash Items | $72.7M |
| Investing cash flowInvesting Cash Flow | -$31.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$31.8M |
| Capital expenditureCapital Expenditure | -$25.9M |
| Purchase of PP&EPurchase Of PPE | -$910.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$910.0k |
| Purchase of investmentsPurchase Of Investment | -$1.0B |
| Sale of investmentsSale Of Investment | $1.0B |
| Net investment purchases and salesNet Investment Purchase And Sale | -$5.9M |
| Purchase of intangiblesPurchase Of Intangibles | -$25.0M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$25.0M |
| Financing cash flowFinancing Cash Flow | $426.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $426.0M |
| Shares issuedIssuance Of Capital Stock | $398.1M |
| Common stock issuedCommon Stock Issuance | $398.1M |
| Net common stock issuedNet Common Stock Issuance | $398.1M |
| Stock options exercisedProceeds From Stock Option Exercised | $27.9M |
| Change in cashChanges In Cash | $49.2M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 10.0% |
| Cash at the start of the yearBeginning Cash Position | $309.8M |
| Cash at the end of the yearEnd Cash Position | $359.1M |
| Free cash flowFree Cash Flow | -$370.9M |
Learn while you research
Academy chapters picked for CRISPR Therapeutics AG and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read